<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> AP900828-0202 </DOCNO><FILEID>AP-NR-08-28-90 2135EST</FILEID><FIRST>r f AM-KodakSued     08-28 0270</FIRST><SECOND>AM-Kodak Sued,0280</SECOND><HEAD>Eastman Kodak Sued by Spinal Disease Sufferers</HEAD><NOTE>Eds: Pharmacal in 4th graf is cq</NOTE><DATELINE>NEWARK, N.J. (AP) </DATELINE><TEXT>   Victims of a debilitating spinal nervedisease sued Eastman Kodak Co. and four other companies Tuesdayover a dye used for diagnostic purposes, the attorney for the classaction said.   The 25 plaintiffs, who live in 18 states, allege they were notadequately informed of the dangers of Pantopaque, a dye injectedinto the spinal membrane for diagnostic purposes.   Eastman Kodak is the principal manufacturer of iophendylate, thesole active ingredient in Pantopaque.   Also named in the lawsuit are Alcon Pharmaceutical LaboratoriesInc. of Fort Worth, Texas; Alcon Puerto Rico Inc. in Humacao,Puerto Rico; Lafayette Pharmaceutical Inc. of Fort Worth; andLafayette Pharmacal Inc., which operated in Indianapolis but hassince been acquired by Alcon.   The four firms assisted Rochester, N.Y.-based Kodak inmanufacturing, marketing and distributing the dye, which has beenon the market since the 1950s, according to the lawsuit filed inU.S. District Court in Newark.   The lawsuit said the plaintiffs had the substance injected intotheir spine at least once to diagnose back or spinal injuries. Theyblame the dye for causing arachnoiditis, an inflammation of thearachnoid membrane that envelopes the brain and spinal cord.   Victims of arachnoiditis suffer from ailments ranging fromchronic pain to quadriplegia to death, said Gary Meyers, theplaintiffs' attorney.   The plaintiffs live in Alabama, Arizona, California, Florida,Illinois, Iowa, Louisiana, Massachusetts, Mississippi, Missouri,Nebraska, North Carolina, Oklahoma, Oregon, Pennsylvania,Tennessee, Utah and Wisconsin.   The lawsuit was filed in New Jersey because Eastman Kodak isincorporated there.</TEXT></DOC>